Countries including Germany, France and Italy have stopped administering the AstraZeneca vaccine.

Ms Stephen-Smith said ACT Health would continue to take the Therapeutic Goods Administration advice on the jab.

The ACT will triple its vaccination rate this week after, with more than 3000 Pfizer and AstraZeneca injections to be given as part of the Australia-wide rollout. The bulk of those - about 2900 - will be the Pfizer vaccine. There will be 600 AstraZeneca doses, Ms Stephen-Smith said.

More than 3000 Canberrans have already been vaccinated, with some getting their second dose of the Pfizer vaccine on Monday.

"At the moment, there is no evidence that the AstraZeneca vaccine is directly related to blood clots or any of those issues," Ms Stephen-Smith said on ABC Canberra.

"The action taken by those few European countries are very precautionary."

Ms Stephen-Smith echoed Chief Medical Officer Paul Kelly's statement about the AstraZeneca vaccine.

"The AstraZeneca COVID-19 vaccine is effective, it is safe, and it's a high-quality vaccine," Mr Kelly said

"Vaccination programs with the AstraZeneca COVID-19 vaccine are continuing in other countries."

Read More:

Ms Stephen-Smith said there was no proof that the AstraZeneca vaccine caused health issues.

"There are underlying health issues right across the community, and so it is not surprising that some people will have a health issue that emerges that isn't related to the vaccine," she said.

"It's really important to monitor these things and to do very quick and very thorough assessments over if it is related to the [vaccine]."

Ms Stephen-Smith said ACT Health planned to administer 3500 vaccinations over the week.

Germany, France and Italy say they will stop administering the AstraZeneca COVID-19 vaccine after several countries reported possible serious side-effects despite an appeal by the World Health Organisation not to suspend inoculations.

Denmark and Norway stopped giving the shot last week after reporting isolated cases of bleeding, blood clots and a low platelet count.

Iceland and Bulgaria followed suit and Ireland and the Netherlands announced suspensions on Sunday.

The moves by some of Europe's largest and most populous countries will deepen concerns about the slow rollout of vaccines in the region, which has been plagued by shortages due to problems producing vaccines including AstraZeneca's.

Germany warned last week it was facing a third wave of infections, Italy is intensifying lockdowns and hospitals in the Paris region are close to being overloaded.

German Health Minister Jens Spahn said that although the risk of blood clots was low, it could not be ruled out.

"This is a professional decision, not a political one," Spahn said adding he was following a recommendation of the Paul Ehrlich Institute, Germany's vaccine regulator.

France said it was suspending the vaccine's use pending an assessment by the EU medicine regulator due on Tuesday.

Italy said its halt was a "precautionary and temporary measure" pending the regulator's ruling.

Austria and Spain have stopped using particular batches and prosecutors in the northern Italian region of Piedmont earlier seized 393,600 doses following the death of a man hours after he was vaccinated.

It was the second region to do so after Sicily, where two people had died shortly after having their shots.

The World Health Organisation earlier on Monday appealed to countries not to suspend vaccinations against a disease that has caused more than 2.7 million deaths worldwide.

"As of today, there is no evidence that the incidents are caused by the vaccine and it is important that vaccination campaigns continue so that we can save lives and stem severe disease from the virus," WHO spokesman Christian Lindmeier said.

The United Kingdom said it had no concerns while Poland said it thought the benefits outweighed any risks.

AstraZeneca's shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019 and is set to be the mainstay of vaccination programs in much of the developing world.

Thailand announced plans on Monday to go ahead with the Anglo-Swedish firm's shot after suspending its use on Friday but Indonesia said it would wait for the WHO to report.

The WHO said its advisory panel was reviewing reports related to the vaccine and would release its findings as soon as possible.

But it said it was unlikely to change its recommendations, issued last month, for widespread use including in countries where the South African variant of the virus may reduce its efficacy.

The European Medicines Agency (EMA) has also said there was no indication the events were caused by the vaccination and that the number of reported blood clots was no higher than seen in the general population.

The handful of reported side-effects in Europe have upset vaccination programs already under pressure over slow roll-outs and vaccine scepticism in some countries.

The Netherlands said on Monday it had registered 10 cases of possible noteworthy adverse side-effects from the AstraZeneca vaccine, hours after the government put its vaccination program on hold following reports of potential side-effects in other countries.

Denmark reported "highly unusual" symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.

"It was an unusual course of illness around the death that made the Danish Medicines Agency react," the agency said in a statement late on Sunday.

One of the three health workers hospitalised in Norway after receiving the AstraZeneca shot had died, health authorities said on Monday, but there was no evidence that the vaccine was the cause.

They said they would continue their probe and that no more suspected cases had been reported since Saturday.

AstraZeneca said earlier it had conducted a review covering more than 17 million people vaccinated in the European Union and the UK which had shown no evidence of an increased risk of blood clots.

Investigations into potential side-effects are complicated as the history of each case and circumstances surrounding a death or illness are examined.

Austrian authorities have said their review of the AstraZeneca batch will take about two weeks.

The EMA has said that as of March 10, a total of 30 cases of blood clotting had been reported among close to 5 million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.

The WHO said that as of March 12, more than 300 million doses of COVID-19 vaccines had been administered around the world with no deaths caused by any of them.

Our journalists work hard to provide local, up-to-date news to the community. This is how you can continue to access our trusted content: